WEBULL
WebtradeDownload

Novo Nordisk (NVO) Could Be 57% Undervalued As Buyback Puts Fair Value In Focus

Simply Wall St · 1d ago

Share repurchase move puts Novo Nordisk in focus

Novo Nordisk (NVO) is back on investors radar after launching a share repurchase programme of up to DKK 15b over 12 months, with B share buybacks running through early 2027.

The buyback arrives after a rough stretch for Novo Nordisk’s investors, with the share price at $38.06 and the 90 day share price return down 24.7%, while the 1 year total shareholder return has declined 30.5% and the 3 year total shareholder return has dropped 60%.

Compare Novo Nordisk's setback with other companies that have stumbled recently, yet still screen well on quality and value, by scanning our hand picked 32 high quality undervalued stocks.

Buybacks at a falling share price raise a blunt question for Novo Nordisk investors. Does fair value sit closer to the current $38.06 level, or nearer the richer analyst and intrinsic estimates that point higher?

Most Popular Narrative: 63% Undervalued

Novo Nordisk’s most followed valuation story pegs fair value at $102.97, far above the last close at $38.06. This frames the current buyback against a wide narrative gap.

Assuming revenue growth stabilizes at 50% of its historical levels, margins grow from 33% to 35%, and it returns to a P/E of 22 (the current average for the pharmaceutical sector), we see its current fair value at $102.97 making NVO 57.4% undervalued at current prices. We believe the market will continue to undervalue NVO in 2026, but think the share price could reach $62 by the end of the year based solely on the success of its oral GLP-1 products.

See why 68 investors see Novo Nordisk as 63% undervalued.

Result: Fair Value of $102.97 (UNDERVALUED)

Still, the Novo Nordisk story can break. Regulatory setbacks for oral GLP 1 treatments or slower than expected adoption in key markets would quickly challenge this bullish narrative.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

The valuation debate around Novo Nordisk is intense right now, with both risks and rewards clearly on display. Act quickly, review the full breakdown, and weigh those trade offs using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

Novo Nordisk may be front of mind today, but your next opportunity could be sitting elsewhere, and you do not want to leave those possibilities unchecked.

  • Target reliable income streams by scanning for companies that qualify as 8 dividend fortresses and see which payouts look more resilient on the numbers.
  • Pressure test your downside risk by reviewing a curated 32 resilient stocks with low risk scores that focuses on resilience when conditions get choppy.
  • Hunt for underfollowed opportunities by searching through a 20 high quality undiscovered gems that filters for quality fundamentals before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.